Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Infectious Disease ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Cytokine Storm.N Engl J Med. 2020; 383: 2255-2273
- Cytokine storm of graft-versus-host disease: a critical effector role for interleukin-1.Transplant Proc. 1993; 25: 1216-1217
- The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3).JAMA. 2016; 315: 801-810
- Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.Mol Ther. 2010; 18: 843-851
- ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.Biol Blood Marrow Transplant. 2019; 25: 625-638
- Managing the toxicities of CAR T-cell therapy.Hematol Oncol. 2019; 37: 48-52
- Next generation of immune checkpoint inhibitors and beyond.J Hematol Oncol. 2021; 14: 45
- Delayed cytokine release syndrome after neoadjuvant nivolumab: a case report and literature review.Immunotherapy. 2021; 13: 1071-1078
- Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.Front Pharmacol. 2020; 11: 557
- Cytokine Release Syndrome in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Case Series of 25 Patients and Review of the Literature.Front Immunol. 2022; 13: 807050
- NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020.J Natl Compr Canc Netw. 2020; 18: 230-241
- Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.N Engl J Med. 2018; 378: 158-168
- Immune Checkpoint Inhibition in Sepsis: A Phase 1b Randomized, Placebo-Controlled, Single Ascending Dose Study of Antiprogrammed Cell Death-Ligand 1 Antibody (BMS-936559).Crit Care Med. 2019; 47: 632-642
- The late phase of sepsis is characterized by an increased microbiological burden and death rate.Crit Care. 2011; 15: R183
- Immunosuppression in patients who die of sepsis and multiple organ failure.JAMA. 2011; 306: 2594-2605
- Immune checkpoints and their inhibition in cancer and infectious diseases.Eur J Immunol. 2017; 47: 765-779
- Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.N Engl J Med. 2019; 380: 1597-1605
- Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.J Clin Oncol. 2018; 36: 1714-1768
- Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).Blood. 1999; 94: 2217-2224
- The anti-CD3-induced syndrome: a consequence of massive in vivo cell activation.Curr Top Microbiol Immunol. 1991; 174: 121-134
- Monoclonal antibody-induced cytokine-release syndrome.Expert Rev Clin Immunol. 2009; 5: 499-521
- Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy.Blood. 2013; 121: 5154-5157
- Tagraxofusp in Blastic Plasmacytoid Dendritic-Cell Neoplasm.N Engl J Med. 2019; 380: 1628-1637
- HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide.Biol Blood Marrow Transplant. 2008; 14: 641-650
- Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis.Bone Marrow Transplant. 2021; 56: 2763-2770
- Grade 3-4 cytokine release syndrome is associated with poor survival in haploidentical peripheral blood stem cell transplantation.Leuk Lymphoma. 2021; 62: 1982-1989
- Cytokine Release Syndrome Following Peripheral Blood Stem Cell Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide.Transplant Cell Ther. 2022; 28: 111.e1-8
- Severe Cytokine Release Syndrome after Haploidentical Peripheral Blood Stem Cell Transplantation.Biol Blood Marrow Transplant. 2019; 25: 2431-2437
- High plasma IL-6 levels following haploidentical allogeneic hematopoietic stem cell transplantation post-transplant cyclophosphamide as predictor of early death and worse outcome.Transpl Immunol. 2022; 71: 101543
- Clinical Impacts of Using Serum IL-6 Level as an Indicator of Cytokine Release Syndrome after HLA-Haploidentical Transplantation with Post-Transplantation Cyclophosphamide.Biol Blood Marrow Transplant. 2019; 25: 2061-2069
- Severe Cytokine-Release Syndrome after T Cell-Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Anti-IL-6 Therapy Is Safe and Well Tolerated.Biol Blood Marrow Transplant. 2016; 22: 1851-1860
- Critical Care of Hematopoietic Stem Cell Transplant Patients.Crit Care Clin. 2021; 37: 29-46
- Case Report: Fatal Complications of BK Virus-Hemorrhagic Cystitis and Severe Cytokine Release Syndrome Following BK Virus-Specific T-Cells.Front Immunol. 2021; 12: 801281
- Off-the-Shelf Virus-Specific T Cells to Treat BK Virus, Human Herpesvirus 6, Cytomegalovirus, Epstein-Barr Virus, and Adenovirus Infections After Allogeneic Hematopoietic Stem-Cell Transplantation.J Clin Oncol. 2017; 35: 3547-3557
- Cellular therapy for multiple pathogen infections after hematopoietic stem cell transplant.Cytotherapy. 2017; 19: 1284-1301
- Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.Sci Transl Med. 2014; 6: 242ra283
- Immunotherapy with Donor T Cells Sensitized with Overlapping Pentadecapeptides for Treatment of Persistent Cytomegalovirus Infection or Viremia.Biol Blood Marrow Transplant. 2015; 21: 1663-1678
- Virus-specific T-cell therapies for patients with primary immune deficiency.Blood. 2020; 135: 620-628
- Hemophagocytic lymphohistiocytosis: review of etiologies and management.J Blood Med. 2014; 5: 69-86
- HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis.Pediatr Blood Cancer. 2007; 48: 124-131
- The Immunology of Macrophage Activation Syndrome.Front Immunol. 2019; 10: 119
- A prospective quality improvement initiative in adult hemophagocytic lymphohistiocytosis to improve testing and a framework to facilitate trigger identification and mitigate hemorrhage from retrospective analysis.Medicine (Baltimore). 2018; 97: e11579
- Hyperferritinemia in Critically Ill Patients.Crit Care Med. 2020; 48: 459-465
- Chimeric antigen receptor T-cell therapy - assessment and management of toxicities.Nat Rev Clin Oncol. 2018; 15: 47-62
- Pathogenesis of the immune reconstitution inflammatory syndrome in HIV-infected patients.Curr Opin Infect Dis. 2012; 25: 312-320
- HIV-Associated Cancers and Related Diseases.N Engl J Med. 2018; 378: 1029-1041
- Characteristics and outcomes of KSHV-associated multicentric Castleman disease with or without other KSHV diseases.Blood Adv. 2021; 5: 1660-1670
- The Potential Clinical Benefit of Tocilizumab Therapy for Patients with HHV-8-infected AIDS-related Multicentric Castleman Disease: A Case Report and Literature Review.Cureus. 2020; 12: e7589
- Tocilizumab in patients with symptomatic Kaposi sarcoma herpesvirus-associated multicentric Castleman disease.Blood. 2020; 135: 2316-2319
- Capillary leak syndrome: etiologies, pathophysiology, and management.Kidney Int. 2017; 92: 37-46
- Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer.Crit Care Med. 2020; 48: 10-21
- Cytokine release syndrome.J Immunother Cancer. 2018; 6: 56
- New drugs, new toxicities: severe side effects of modern targeted and immunotherapy of cancer and their management.Crit Care. 2017; 21: 89
- The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.Am Soc Clin Oncol Educ Book. 2019; 39: 433-444
- Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.Biol Blood Marrow Transplant. 2020; 26: 26-33
- FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome.Oncologist. 2018; 23: 943-947
- Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study.Crit Care Med. 2022; 50: 81-92
- Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.Blood Rev. 2019; 34: 45-55
- New Decade, Old Debate: Blocking the Cytokine Pathways in Infection-Induced Cytokine Cascade.Crit Care Explor. 2021; 3: e0364
- Management of the Critically Ill Adult Chimeric Antigen Receptor-T Cell Therapy Patient: A Critical Care Perspective.Crit Care Med. 2018; 46: 1402-1410
- Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma.Blood. 2021; 137: 3272-3276
- Hydrocortisone plus Fludrocortisone for Adults with Septic Shock.N Engl J Med. 2018; 378: 809-818
- Adjunctive Glucocorticoid Therapy in Patients with Septic Shock.N Engl J Med. 2018; 378: 797-808
- Sepsis and septic shock: Guideline-based management.Cleve Clin J Med. 2020; 87: 53-64
- The Surviving Sepsis Campaign: Fluid Resuscitation and Vasopressor Therapy Research Priorities in Adult Patients.Crit Care Med. 2021; 49: 623-635
- The chimeric antigen receptor-intensive care unit (CAR-ICU) initiative: Surveying intensive care unit practices in the management of CAR T-cell associated toxicities.J Crit Care. 2020; 58: 58-64
- Time to Treatment and Mortality during Mandated Emergency Care for Sepsis.N Engl J Med. 2017; 376: 2235-2244
- Infectious complications of CD19-targeted chimeric antigen receptor-modified T-cell immunotherapy.Blood. 2018; 131: 121-130
- Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).Haematologica. 2020; 105: 297-316
- Infections after anti-CD19 chimeric antigen receptor T-cell therapy for hematologic malignancies: timeline, prevention, and uncertainties.Curr Opin Infect Dis. 2020; 33: 449-457
- How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies.Blood. 2020; 136: 925-935
- COVID-19: consider cytokine storm syndromes and immunosuppression.Lancet. 2020; 395: 1033-1034
- Dexamethasone in Hospitalized Patients with Covid-19.N Engl J Med. 2021; 384: 693-704
- Effect of Tocilizumab vs Usual Care in Adults Hospitalized With COVID-19 and Moderate or Severe Pneumonia: A Randomized Clinical Trial.JAMA Intern Med. 2021; 181: 32-40
- Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia.N Engl J Med. 2021; 384: 20-30
- Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.N Engl J Med. 2021; 384: 1491-1502
- Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19.N Engl J Med. 2021; 384: 795-807
- Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.Lancet Respir Med. 2021; 9: 1407-1418
- Malignancy-associated haemophagocytic lymphohistiocytosis.Lancet Haematol. 2022; 9: e217-e227
- Multisystem inflammatory syndrome in children and adults (MIS-C/A): Case definition & guidelines for data collection, analysis, and presentation of immunization safety data.Vaccine. 2021; 39: 3037-3049
- Multisystem Inflammatory Syndrome in U.S. Children and Adolescents.N Engl J Med. 2020; 383: 334-346
- Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors.Clin Microbiol Infect. 2021; 27: 451-457
- Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review To Support COVID-19 Antimicrobial Prescribing.Clin Infect Dis. 2020; 71: 2459-2468
- C-reactive protein and procalcitonin for antimicrobial stewardship in COVID-19.Infection. 2021; 49: 935-943
Article info
Identification
Copyright
Published by Elsevier Inc.
